About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ADMS - Adamas Pharmaceutica...| Previous Close | $4.76 | Open | |
| Volume | Market Cap | 126.93M | |
| Yield | Last Dividend |
| The Daily Biotech Pulse: Adamas Rallies ... | 06/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Bioh... | |
| All You Need to Know About Adamas (ADMS)... | 04/28/20 |
| Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| Adamas Pharma EPS misses by $0.02, beats... | 02/25/20 |
| Adamas Pharma (NASDAQ:ADMS): Q4 GAAP EPS of -$0.83 misses by $0.02. Revenue of $16.35M (+22.7% Y/Y) beats by $0.09M. Shares +1.7%. Press Release | |
| ALERT: ROSEN, NATIONAL INVESTOR COUNSEL,... | 02/05/20 |
| NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceutica... | |
| ADMS INVESTOR DEADLINE IN 7 DAYS: Bernst... | 02/03/20 |
| NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plain... | |
| GE T&D bags Rs 173 cr JKPDD contract | 01/23/20 |
| GE T&D India on Thursday said it bagged a Supervisory Control and Data Acquisition (SCADA) and Advanced Distribution Management Solution (ADMS) projec... | |
| ADMS ROSEN, A TOP LAW FIRM, Reminds Adam... | 01/04/20 |
| NEW YORK, Jan. 04, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. bet... | |
| Glancy Prongay & Murray Reminds Investor... | 12/20/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharm... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 12/17/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS #ADMS--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuti... | |
| Adamas drug to help MS patients walk doe... | 12/17/19 |
| REUTERS: Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with multiple sclerosis did not show the ??? | |
| Is Adamas Pharmaceuticals Inc (ADMS) A G... | 12/16/19 |
| With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world pr... | |
| ADMS LOSS NOTICE ALERT: TOP RANKED Rosen... | 12/14/19 |
| NEW YORK, Dec. 14, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of... | |
| Adamas Pharmaceuticals : Glancy Prongay ... | 12/13/19 |
| Glancy Prongay & Murray LLP , a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that a... | |
| Glancy Prongay & Murray LLP Announces th... | 12/13/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceutic... | |
| Shareholder Alert: Robbins LLP Announces... | 12/12/19 |
| SAN DIEGO & EMERYVILLE, Calif.--(BUSINESS WIRE)---- $ADMS #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Adamas P... | |
| Glancy Prongay & Murray LLP Announces In... | 12/12/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors | |
| ADMS INVESTOR ALERT: Bernstein Liebhard ... | 12/12/19 |
| NEW YORK, Dec. 12, 2019 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action ... | |
| IMPORTANT INVESTOR ALERT: The Schall Law... | 12/11/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS #ADMS--IMPORTANT INVESTOR ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceut... | |
| The Daily Biotech Pulse: Therapix Extend... | 10/11/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs O... | |
| The Daily Biotech Pulse: UCB To Buy Ra P... | 10/10/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) A... | |
| The Daily Biotech Pulse: FDA Approves Cl... | 10/09/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-we... | |
| The Daily Biotech Pulse: Arbutus Halts H... | 10/04/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Ap... | |
| Adamas Pharmaceuticals (ADMS) May Report... | 08/01/19 |
| Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| Will Adamas Pharmaceuticals Continue to ... | 06/25/19 |
| As of late, it has definitely been a great time to be an investor Adamas Pharmaceuticals. | |
| The Daily Biotech Pulse: Positive Readou... | 06/19/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) ... | |
| What Makes Adamas (ADMS) a New Buy Stock | 06/18/19 |
| Adamas (ADMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the sto... | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | ($0.61)/ 15.32M |
| Actual (EPS/Rev.) | $-0.37/ $18.79 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
